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ll of the articles in this issue of 
 
Value in
Health
 
 are concerned in some fashion with
drawing inferences about the costs and conse-
quences of drug therapy from real world data;
that is, data from observational or retrospective
databases not designed specifically for research
purposes. Research study designs are character-
ized in Table 1 [1].
Each study design has differing strengths and
weaknesses, depending on data availability, time,
and budget constraints [2–4]. The FDA and other
drug regulatory agencies mandate prospective ex-
perimental study designs of the RCT type, because
they need to know whether drugs are safe and effi-
cacious when used as ideally intended. In a cost-
constrained environment, health care purchasers,
providers, and policymakers have to be as inter-
ested in real-world drug use where poor compli-
ance, heterogeneous populations, treatment or
provider selection biases, and treatment interac-
tions can cloud or alter RCT study results. Retro-
spective and observational studies are appealing to
decision-makers because they address these points.
Moreover, they can be significantly cheaper and
quicker to conduct; but they are useful only when
their limitations are properly acknowledged and
dealt with.
In this issue, some valuable theoretical tools
and empirical examples of retrospective data anal-
ysis are provided. In the tool kit, the Liu and Zhao
paper [5] and the Terza paper [6] deal with impor-
tant empirical methodological concerns that affect
most retrospective and observational study de-
signs. Liu and Zhao examine the conditions under
which a system of equations for costs and out-
comes (effectiveness) can be estimated to yield effi-
cient and unbiased measures of the incremental
cost-effectiveness associated with a new (or alter-
native) treatment. While it is well-known that sta-
tistical confidence intervals for empirical cost-effec-
tiveness ratios are complex [7,8], Liu and Zhao
point out that inadequate control for confounders,
both observed and unobserved, can alter the valid-
ity of C-E estimates and confidence interval calcu-
lations, unless quite restrictive empirical condi-
tions hold (e.g., randomized treatment assignment).
Their two-step simultaneous equations solution is
a clever and feasible method for solving these
problems.
One of the important concerns in empirical
evaluation of retrospective data is that in the real
world, patients are not randomly assigned to
treatment. This “selection bias” can substantially
alter statistical inferences. As an example, several
years ago I examined data from a Michigan HMO
looking at the costs of treating acute back pain
with alternative pain-relief medications. One of
the medications was associated with substantially
higher treatment costs per episode, but this drug
was also much more likely to be utilized by pa-
tients with the most severe levels of back pain. Ig-
noring this nonrandom treatment selection by
providers and patients would have led to the con-
clusion that the medication, which had below av-
erage treatment costs per episode when level of
back pain was controlled for, was relatively more
expensive.
Clearly, if all possible confounders are known
and measured, it would be a straightforward task
to adjust findings for selection bias. But particu-
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Table 1
 
Categorization of Pharmacoeconomic and 
Outcomes Research Study Designs
 
Experimental Observational
Retrospective Natural Experiment Typical Database Analysis
Prospective Randomized 
controlled
trial (RCT)
Typical Demonstration
Project
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larly with retrospective data, many important con-
founders are unobservable or not available for
analysis. Unfortunately, the unobservable error
components affecting choice of treatment are of-
ten correlated with the unobservable error compo-
nents affecting the cost or outcomes associated
with treatment alternatives. This can bias the esti-
mates.
Statistical techniques for dealing with selection
bias have been available for more than two de-
cades [9], but are not always adequately consid-
ered in pharmacoeconomic analyses of retrospec-
tive data. Madalla’s 1983 text gives a comprehensive
review of relevant econometric considerations
[10], and there are more recent expositions [11].
Terza’s paper in this issue provides a useful, flexi-
ble two-stage approach to estimation of treatment
effects in the presence of potential selection bias
when examining retrospective data for linear,
counting data, and other nonlinear estimation
models [6]. At this point, given the availability of
literature and software, there is no excuse for re-
searchers to ignore possible selection bias effects
when comparing alternative drug treatments with
retrospective and observational data.
Neslusan et al. provide a specific application of
Terza’s estimation methodology to evaluation of
retrospective data on antidepressant therapy [12].
They evaluate two outcome measures for drug
treatment comparing fluoxetine and sertraline. In
the equation estimating duration of SSRI therapy,
they found no significant selection bias effects,
while in the equation estimating the probability of
exceeding the minimum daily dose, they found se-
lection effects to be significant, biasing the esti-
mated coefficient for sertraline upwards by about
one-third. Clearly, detection and correction for se-
lection bias effects was warranted in this case.
The fact that sertraline exhibited a significantly
shorter duration of therapy and a larger likelihood
of dose exceeding the suggested minimum daily
dose raises some intriguing questions of interpre-
tation that are also typical in retrospective data-
base analyses. In their discussion, Neslusan et al.
indicate that it was not possible to assess the clini-
cal outcomes associated with the different patterns
of use observed with fluoxetine or sertraline be-
cause clinical outcome measures were not avail-
able in the data. Observational studies can com-
plement the findings from randomized clinical
trials by assessing how the drugs are used in actual
clinical practice by typical patients and practitio-
ners.
Difficulty in interpretation is pervasive in retro-
spective drug compliance studies, as illustrated in
the other two empirical papers by Matuszewski et
al. [13] and Desgagné and LeLorier [14]. Naively,
one might expect that there would be a straight-
forward positive association between rates of
medication noncompliance and increased costs or
deteriorating patient health outcomes, such as
poorer prognosis, higher frequency of hospitaliza-
tion, longer illness episodes, and higher nondrug
treatment expenditures. In the real world, how-
ever, it can be the case that patients with higher
disease severity compensate by being more com-
pliant with drug therapy than patients with lower
disease severity [15]. This can lead to an observed
lack of association between therapy compliance
and favorable outcomes in retrospective data-
bases; and even lead to negative associations. Since
adequate measures of disease severity are seldom
available in administrative databases, treatment
costs, duration, drug effectiveness, and other out-
comes cannot easily or directly be related to choice
of drug, drug compliance, or drug switching be-
havior. This point is not always understood, and
sometimes abused in discussion of retrospective
research findings.
Using careful measurements of drug therapy
compliance for Chronic Obstructive Pulmonary
Disease (COPD), and a comprehensive VA patient
database, Matuszewski et al. find, contrary to ex-
pectations, that there is no difference in medica-
tion compliance between hospitalized and non-
hospitalized COPD patients [13]. As they point
out, medication usage is itself an indicator of both
therapy effectiveness and of underlying disease se-
verity. It is impossible to untangle these opposing
factors. One can estimate real-world noncompli-
ance rates, but with administrative data, one can-
not easily conclude whether noncompliance is caus-
ally associated with specific disease costs or
outcomes.
Desgagné and LeLorier, in a drug therapy com-
pliance investigation of urinary incontinence med-
ication usage, find that around 60% of sample pa-
tients never renewed their first prescription [14].
This is not too surprising to those who have
looked at drug compliance in other therapeutic ar-
eas [16–18], but it raises many questions about
real-world drug effectiveness, and health care re-
source utilization. If patients are not taking drugs
known to be safe and efficacious, why not? What
are the cost, health care utilization, and health sta-
tus consequences of medication abandonment for
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urinary incontinent patients? Desgagné and LeLor-
ier’s study isn’t designed to answer these ques-
tions, but future studies are clearly needed.
Our health care systems devote enormous re-
sources to drug discovery and development, to
drug production quality control, to control of pre-
scribing behavior by physicians, and drug dispens-
ing by pharmacists, but relatively little is known
or done regarding follow-up for patients who dis-
continue their medication as prescribed.
Despite important limitations, retrospective da-
tabase studies will advance medical knowledge by
documenting how drugs are actually used in the
real world, and how different these patterns of
drug usage are from the idealized world of ran-
domized controlled clinical trials. More and better
retrospective research tools and empirical data will
always be in demand. Nevertheless, these studies
will continue to make valuable scientific contribu-
tions to pharmacoeconomics and outcomes re-
search, particularly in showing what happens
when real health care providers treat real patients.
 
Value in Health
 
 encourages submission of meth-
odological and empirical studies using all four of
the study designs described in Table 1. We are
quite supportive of observational and retrospective
studies using real-world data, and believe that the
potential for this type of information to enhance
medical decision-making is tremendous and only
beginning to be realized. But the 
 
VH
 
 editorial staff
and reviewers will vigilantly evaluate whether sub-
missions based on retrospective or observational
data deal appropriately with the internal validity,
bias, and interpretation concerns discussed here.
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